Is Semaglutide with cagrilintide legal in Australia?

The rare blend whose combination has actually been trialled, at scale: co-administered cagrilintide and semaglutide produced 20.4% mean weight loss at week 68 against 3.0% on placebo in 3,417 participants. What research vendors sell under this description is not that product, at that ratio, from that supply chain, and gastrointestinal adverse events affected 79.6% of the combination group in the trial.

This page has to do two jobs at once, and keeping them separate is the whole point. First job: the combination is real and it works.

Mechanism: Semaglutide agonises the GLP-1 receptor. Cagrilintide is a long-acting amylin analogue acting on satiety through amylin receptor signalling in the hindbrain.

Regulatory history: The co-formulated combination has been trialled at phase 3 and is the subject of regulatory filings. A research chemical blend sold under its description is not that product and is not approved.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Semaglutide with cagrilintide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.